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Genotypic testingTesting for tuberculosis (TB) is difficult because there are so many tests available. Except for
the culture-based tests, all others are for screening or add-on tests. On the other hand,
there is an urgent need to develop a rapid TB diagnostic test with good sensitivity and spec-
ificity.
The introduction of liquid culture medium in 1980 (BACTEC 460 radiometric) and later
MGIT was a great improvement in a definitive diagnosis, but still results are not as fast
as needed. After the discovery of IS6110 sequence and the whole genome sequence ofMyco-
bacterium tuberculosis (MTB) many rapid diagnostic tests have been developed based on the
molecular platform. This brought hope that these molecular tests will be the answer to the
need for an ideal rapid test for diagnosis and drug susceptibility testing (DST). Among these
notable molecular tests are Hain’s LPA and Cepheid’s GeneXpert–GeneXpert being the lead-
ing one. Time to results for detection and DST, which used to take 6–8 weeks with solid
media, was reduced to 4 weeks by the BACTEC method and now to 2 h by the GeneXpert.
Despite significant improvement in the time to report, molecular-based tests still face
many challenges. Sensitivity and specificity of a diagnostic test is critical in infectious dis-
eases. For molecular tests lack of sensitivity in smear-negative TB cases is a great concern.
In case of DST it is important to have a test which can detect resistance to first-line and
most of the second-line drugs with high sensitivity and specificity. At present the genotypic
tests are applicable for only a few drugs, while GeneXpert detects only Rifampicin resis-
tance. Because of these limitations, genotypic tests are considered as good screening tests.
Until the molecular tests are made more sensitive for the detection of TB and more knowl-
edge is acquired on molecular mechanisms of drug resistance, these tests will remain as
screening tools.
Sustainability is another issue. Presently, funding agencies are supporting the high cost
of the genotypic tests, but what if these funds dry out? This overall situation has created
a dilemma of what should be the right option in choosing a TB diagnostic test. Efforts
are being made to improve the sensitivity and specificity of molecular tests. Until then, it
appears that phenotypic tests, especially using liquid medium, still remain as the only
one offering a comprehensive solution in TB diagnosis and DST. There is still a need for
a diagnostic test which is simple, rapid and affordable for the low-income, high-TB preva-
lence countries, and as comprehensive, sensitive and specific as the liquid culture for TB
diagnosis and DST.
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